Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.44 |
| ▸ | JAK2 | O60674 | 16/20 | 0.44 |
| ▸ | JAK3 | P52333 | 16/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371598 | 0.91 | JAK2 (0.56) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL1368764 | 0.91 | JAK2 (0.56) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL1370195 | 0.88 | DGAT1 (0.38) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL2387681 | 0.88 | DGAT1 (0.38) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL1371116 | 0.85 | JAK2 (0.50) | JAK1JAK2JAK3DGAT1 | |
| SCHEMBL1369915 | 0.85 | JAK2 (0.44) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL12449399 | 0.84 | JAK2 (0.53) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL17403295 | 0.84 | JAK1 (0.40) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL2384175 | 0.84 | DGAT1 (0.40) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL17403293 | 0.83 | JAK1 (0.39) | JAK1JAK2JAK3TYK2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011117160-A1 | PYRROLOPYRAZINE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230414-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK1 5/4885JAK2 3/4885JAK3 7/4885 |
| US-20110230414-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK1 6/4885JAK2 3/4885JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.